Cerevance

Executive Summary

Cerevance is a private, clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders using its proprietary NETSseq platform, which enables precise identification of disease-relevant targets. The company's lead candidate, CVN424, is an oral, non-dopaminergic therapy for Parkinson's disease (PD) that has demonstrated positive Phase 2a data, showing improvements in motor and non-motor symptoms without dopaminergic side effects. Cerevance is now advancing CVN424 into Phase 3 clinical trials, positioning it as a potential first-in-class treatment for PD. Additionally, the company is exploring CVN766 for schizophrenia, which is in Phase 1 development. With a strong cash position and a robust pipeline, Cerevance represents a compelling opportunity in CNS drug development, targeting large unmet needs with a differentiated mechanism of action. Key upcoming milestones include the initiation of Phase 3 trials for CVN424 and potential partnership deals, which could significantly de-risk the program and enhance shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 initiation for CVN424 in Parkinson's disease80% success
• Q2 2026Phase 1 data readout for CVN766 in schizophrenia60% success
• TBDPotential strategic partnership for NETSseq platform or pipeline assets50% success